WUHAN, CHINA, October 26, 2020--MGI’s ground-breaking ceremony of “Intelligent Manufacturing and R&D Base” was officially launched in Guanggu Wuhan. The R&D Base is located at Shendun Road 2, East Lake New Technology Development Zone, Wuhan, with an infrastructure investment of 1.264 billion yuan and a total investment of 2.4 billion yuan. The project is expected to complete the first phase in 2022 with a total construction area of 86,000 square meters.

At the ground-breaking ceremony, Wang Zhonglin, member of the Standing Committee of the CPC Hubei Provincial Committee and Secretary of the CPC Wuhan Municipal Committee, announce the commencement of the project. Zhou Xianwang, Deputy Secretary of the CPC Wuhan Municipal Committee and Mayor of Wuhan, and Wang Xiangwang, member of the Standing Committee of the CPC Wuhan Municipal Committee and Secretary of the Working Committee of East Lake High-tech Zone, delivered a speech respectively.

Wang Jian, Chairman of MGI, expressed his gratitude to the Wuhan Municipal Government for its strong support and introduced the overall situation of the project. He emphasized that Wuhan is a heroic city, which has always had an indissoluble bond with MGI, and MGI was also one of the earliest organizations to set up branches in Guanggu, Wuhan. 

Founded in 2016, MGI has more than 1600 employees, 32% of whom are R&D personnel. MGI operates in 50 countries and regions. MGI is one of the three companies in the world that have the ability to independently develop and mass-produce clinical high-throughput gene sequencers. At present, MGI has 8 branches including Changchun, Wuhan, Qingdao, and Hongkong in China, Kobe in Japan, Dubai in UAE, Riga in Latvia, and San Jose in the USA.

Model display of MGI’s products

Notably, Wuhan is currently an important production base of MGI in China. With the commencement and construction of MGI's intelligent manufacturing and R&D base, MGI will continue to increase a high proportion of R&D investment and build a series of projects in Guanggu Wuhan. These projects include but are not limited to gene sequencer intelligent production base, gene sequencer supporting reagents and chip production base, and high-end intelligent equipment research center. These will also further consolidate Wuhan's position as an important production and R&D base of MGI.

Architectural rendering of MGI’s “Intelligent Manufacturing and R&D Base”

“The life sciences and medical and health industries have always been highly valued by the Wuhan Municipal Government. We hope to establish a world-class production quality system in Wuhan, improve production and delivery capabilities, continuously break through technological limits, and insist on continuous strategic investment in cutting-edge basic research and key technologies. Today’s investment will be transformed into tomorrow’s core competitiveness, and through continuous technological transformation, we will provide an industry-leading digital life technology platform.” Said Mu Feng, CEO of MGI. “At the same time, with the domestically-made, independent and controllable core tools, we will drive the joint development of life sciences from scientific research to industry to people’s livelihood, and build an open, cooperative and win-win industrial ecosystem. We aim to promote life sciences to benefit the public’s health, the national economy, and people’s livelihood, and accelerate the realization of “innovative and intelligent manufacturing”.